Genmab shared Phase 3 trial results for epcoritamab in lymphoma, missing overall survival but improving disease control, as analyst weighs approval risks and future trial data.
Why Is Genmab Stock Falling Today
Genmab shared Phase 3 trial results for epcoritamab in lymphoma, missing overall survival but improving disease control, as analyst weighs approval risks and future trial data.
